Barclays

Barclays’s AEON Biopharma Inc AEON.WS Stock Holding History

Barclays’s Portfolio AEON.WS Stock Details AEON.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-144	Closed	-$7	–	5438
2022 Q4	$7	Buy	+144	New	+$6	﹤0.01%	5247

Other funds holding AEON.WS

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

Parallax Volatility Advisers

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Barclays's AEON.WS Position: Q1 2023 in Review

Barclays sold out of AEON Biopharma Inc (AEON.WS) in Q1 2023, closing a stake of 144 shares — an estimated $7 sold.

Barclays first reported a position in AEON.WS in Q4 2022 and held it in 1 quarter. The position peaked at $7 in Q4 2022. 49 funds tracked by Wall St. Rank hold AEON.WS as of Q1 2023.

Barclays reported no remaining AEON Biopharma Inc position as of Q1 2023 after selling out during the quarter.
Barclays sold 144 AEON Biopharma Inc shares in Q1 2023, an estimated $7.
Barclays first reported a position in AEON Biopharma Inc in Q4 2022 and held it in 1 quarter.
Barclays's AEON Biopharma Inc position peaked at $7 in Q4 2022.
49 funds tracked by Wall St. Rank held AEON Biopharma Inc as of Q1 2023.

Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.